Home Cart Sign in  
Chemical Structure| 685898-44-6 Chemical Structure| 685898-44-6

Structure of PX-478·2HCl
CAS No.: 685898-44-6

Chemical Structure| 685898-44-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

PX-478 is an orally active HIF-1α inhibitor with potent antitumor activities that can cross the blood-brain barrier.

Synonyms: PX-478 2HCl; PX-478

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of PX-478·2HCl

CAS No. :685898-44-6
Formula : C13H22Cl4N2O3
M.W : 396.14
SMILES Code : O=C([C@@H](N)CC1=CC=C([N+](CCCl)([O-])CCCl)CC1)O.[H]Cl.[H]Cl
Synonyms :
PX-478 2HCl; PX-478
MDL No. :MFCD11840749
InChI Key :GIGCDIVNDFQKRA-LTCKWSDVSA-N
Pubchem ID :11234794

Safety of PX-478·2HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of PX-478·2HCl

epigenetics

Isoform Comparison

Biological Activity

Target
  • HIF

In Vitro:

Cell Line
Concentration Treated Time Description References
BT-549 cells 30 µM 24 h To evaluate the effect of PX-478 on BT-549 cell proliferation and M2 macrophage polarization, results showed that PX-478 inhibited cell proliferation and M2 polarization. PMC11303452
MDA-MB-231 (triple-negative breast cancer cells) 25 µM 24 h To evaluate the cytotoxicity of PX-478 on triple-negative breast cancer cells, results showed that PX-478 combined with low-dose Doxo had a synergistic effect, significantly reducing cell viability. PMC10324152
C4-2B cells 50 µM 24 h PX-478 induced CC3 and CPARP levels in C4-2B cells, which were further enhanced when combined with enzalutamide PMC10245031
DU-145 cells 50 µM 24 h PX-478 induced CC3 and CPARP levels in DU-145 cells PMC10245031
PC-3 cells 50 µM 24 h PX-478 induced CC3 and CPARP levels in PC-3 cells PMC10245031
C6 glioma cells 0.1 to 200 μM 24 h PX-478 inhibited HIF-1-dependent GFP signaling in C6 cells with an IC50 value of 49.2 μM. PMC2908257
HN5 cells 25 μM 24 h PX-478 inhibited HIF-1 protein expression and reduced VEGF secretion in HN5 cells under hypoxic conditions. PMC2908257
UMSCCA10 cells 25 μM 24 h PX-478 inhibited HIF-1 protein expression and reduced VEGF secretion in UMSCCA10 cells under hypoxic conditions. PMC2908257
Panc-1 pancreatic cancer cells 25 μM 24 h PX-478 provided direct radiosensitization in Panc-1 cells under hypoxic conditions. PMC2908257

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Balb/c mice 4T1 breast cancer model Intraperitoneal injection 30 mg/kg Twice a week for 4 weeks To evaluate the effect of PX-478 on breast cancer progression, results showed that PX-478 inhibited tumor growth and prolonged the survival time of mice. PMC11303452
Mice Wild-type mice Intraperitoneal injection 5 mg/kg 1 hour before each ethanol exposure, lasting for 6 hours PX-478 partially suppressed binge alcohol-mediated increases in HIF-1 α and BNIP3, attenuated iNOS induction and subsequent nitrotyrosine formation, and partially blocked binge alcohol-induced hepatocyte apoptosis and plasma ALT elevation. PMC4304203
Mice Portal hypertension model Oral gavage 5 mg/kg Every other day, duration not specified PX-478 alleviated PHT-mediated mitochondrial dysfunction and oxidative stress in the gastric mucosa, reversed mitochondrial morphological changes, and decreased ROS production. PMC11016940
FVB mice Intramuscular implantation model Intraperitoneal injection 50 mg/kg Every other day injection for 1 week or 2 weeks To investigate the effect of HIF-1α inhibitor PX-478 on macrophage polarization and osteoclastogenesis in MG implants. The results showed that PX-478 significantly inhibited HIF-1α expression, macrophage polarization, and osteoclastogenesis in MG implants. PMC10214238
Mice Pten-deficient mouse model Oral gavage 20 mg/kg Once daily for 3 weeks PX-478 treatment significantly reduced the proportion of adenocarcinoma in Pten-deficient mouse prostate tumors and induced apoptosis in tumor cells PMC10245031
nude mice C6 and HN5 xenograft models oral 30 mg/kg 2 consecutive days PX-478 significantly enhanced the inhibitory effect of single-dose irradiation on C6 and HN5 xenograft tumors in vivo, and achieved radiosensitization by inhibiting HIF-1-dependent tumor stromal adaptation. PMC2908257

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.52mL

0.50mL

0.25mL

12.62mL

2.52mL

1.26mL

25.24mL

5.05mL

2.52mL

References

 

Historical Records

Categories